Table 1.
Results of HCT from DLA-haploidentical donor after CTLA4-Ig/donor PBMC with 200 cGy TBI
| Group | Recipient Dog ID# | Cells Subsets of PBSC Grafts
|
Rejection | Maximum Chimerism Achieved
|
Final Donor Chimerism in MNC (%) | Duration of Mixed Chimerism (weeks) | GVHD | Survival Weeks | Cause of Death | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD34+ (×106/kg) | CD3+ (×107/kg) | CD4+ (×107/kg) | CD8+ (×107/kg) | % in MNC | Weeks | ||||||||
| 1a | E923 | 1.9 | 9.8 | 7.1 | 0.5 | Yes | 0 | / | 0 | 0 | None | 8 | ET2-Rejection |
| E879 | 2.3 | 3.7 | 8.4 | 0.7 | Yes | 0 | / | 0 | 0 | None | 6 | ET2-Rejection | |
| E871 | 10.7 | 24.9 | 22.7 | 5.9 | NE | 78 | 4 | 47 | >5 | None | 7 | ET2 | |
| 2b | E934 | 1.8 | 5.8 | 3.6 | 0.3 | Yes | 43 | 3 | 0 | 15 | None | 19 | ET2-Rejection |
| E932 | 15.1 | 27.6 | 26.2 | 1.0 | Yes | 79 | 4 | 0 | 12 | None | 23 | ET2-Rejection | |
| G024 | 4.4 | 17.3 | 10.7 | 2.3 | Yes | 0 | / | 0 | 0 | None | 6 | ET2-Rejection | |
| 3c | G096 | 2.7 | 36.2 | 24.7 | 0.9 | Yes | 96 | 4 | 0 | 22 | None | 27 | ET2-Rejection |
| G067 | 1.2 | 10.0 | 6.5 | 1.1 | Yes | 47 | 5 | 0 | 12 | None | 13 | ET2-Rejection | |
| 4d | G891 | 1.2 | 32.3 | 2.1 | 6.1 | No | 77 | 12 | 77 | 12 | None | 12 | ET1-PTLD |
| G888 | 0.7 | 40.8 | 27.6 | 4.4 | Yes | 43 | 5 | 0 | 17 | None | 18 | ET2-Rejection | |
| G889 | 1.7 | 43.7 | 27.2 | 5.7 | No | 100 | 19 | 100 | 34 | Yes | 34 | ET1-GVHD | |
| H122 | 3.3 | 18.4 | 10.5 | 3.9 | Yes | 6 | 4 | 0 | 5 | None | 5 | ET1-Intussusception | |
| H141 | 12.0 | 44.4 | 32.6 | 12.9 | Yes | 46 | 7 | 0 | 17 | None | 18 | ET2-Rejection | |
| H211 | 23.0 | 25.0 | 198.0 | 5.4 | Yes | 57 | 3 | 0 | 13 | None | 13 | ET2-Rejection | |
CTLA4-Ig 4 mg/kg i.v. days -7 to -1; Donor PBMC 1×107/kg i.v. days -7 and -3; 200 cGy TBI on day 0 followed by donor PBSC infusion; CSP 30 mg/kg per day from days -1 to day +100; MMF 20 mg/kg per day from day 0 to +40, 10 mg/kg per day from day+41 to +100.
CTLA4-Ig 5 mg/kg i.v. days -10, -8 to -5; 10 mg/kg on days -9 and -4; Donor PBMC 1×107/kg i.v. on days -10 and -5; 200 cGy TBI on day 0 followed by donor PBSC infusion; and same regimen of CSP and MMF as Group 1.
CTLA4-Ig 5 mg/kg i.v. days -10, -8 to -5; 10 mg/kg on days -9, -4, 0 and +1; Donor PBMC 1×107/kg i.v. on days -10 and -5; 200 cGy TBI on day 0 followed by donor PBSC infusion; and same regimen of CSP and MMF as Group 1.
200 cGy TBI on day 0 followed by donor PBSC infusion; CSP 30 mg/kg per day from day -3 to day +180, 15 mg/kg per day from day +181 to day +190, 7.5 mg/kg per day from day +191 to day +200, 3 mg/kg per day from day +200 to day +210; MMF 20 mg/kg per day from day 0 to day+100, 10 mg/kg per day from day +101 to day +130, 5 mg/kg per day from day +131 to day +160, 2.5 mg/kg per day from day +161 to day +180.
Abbreviations: CSP, cyclosporine; DLA, dog leukocyte antigen; ET1, euthanized due to poor conditions; ET2, euthanized in good condition due to the end of study; GVHD, graft-versus-host disease; HCT, hematopoietic cells transplantation; ID#, identifying number; MMF, mycophenolate mofetil; MNC, mononuclear cells; PBMC, peripheral blood mononuclear cells; PBSC, peripheral blood stem cells; PTLD, post-transplant lymphoproliferative disease; NE, not evaluable; TBI, total body irradiation.